Innocan Pharma to issue USD 450,000 10% debenture to Tamar Innovest

Reuters03-12

<a href="https://laohu8.com/S/INNPF">Innocan Pharma</a> to issue USD 450,000 10% debenture to Tamar Innovest

Innocan said it plans to issue a debenture to its largest shareholder, Tamar Innovest, for gross proceeds of USD 450,000. The debenture will pay 10% annual interest and mature in 12 months, or earlier upon completion of the company’s previously announced proposed U.S. public offering. The debenture will be secured under a general security agreement dated March 7, 2025, with related security interests filed in Alberta. Innocan said it expects the offering to close on or around March 12, 2026, and intends to use the proceeds for working capital and NYSE listing-related costs. Tamar Innovest holds 17% of Innocan’s common shares and is managed by Ralph Bossino, a director of the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innocan Pharma Ltd. published the original content used to generate this news brief via CNW (Ref. ID: 202603111842CANADANWCANADAPR_C7838) on March 11, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618971780?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 06:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618971780","market":"fut","top_or_hot":-1,"title":"Innocan Pharma to issue USD 450,000 10% debenture to Tamar Innovest","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/INNPF\">Innocan Pharma</a> to issue USD 450,000 10% debenture to Tamar Innovest\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Innocan said it plans to issue a debenture to its largest shareholder, Tamar Innovest, for gross proceeds of USD 450,000. The debenture will pay 10% annual interest and mature in 12 months, or earlier upon completion of the company’s previously announced proposed U.S. public offering. The debenture will be secured under a general security agreement dated March 7, 2025, with related security interests filed in Alberta. Innocan said it expects the offering to close on or around March 12, 2026, and intends to use the proceeds for working capital and NYSE listing-related costs. Tamar Innovest holds 17% of Innocan’s common shares and is managed by Ralph Bossino, a director of the company.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innocan Pharma Ltd. published the original content used to generate this news brief via CNW (Ref. ID: 202603111842CANADANWCANADAPR_C7838) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innocan Pharma to issue USD 450,000 10% debenture to Tamar Innovest</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnocan Pharma to issue USD 450,000 10% debenture to Tamar Innovest\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 06:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/INNPF\">Innocan Pharma</a> to issue USD 450,000 10% debenture to Tamar Innovest\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Innocan said it plans to issue a debenture to its largest shareholder, Tamar Innovest, for gross proceeds of USD 450,000. The debenture will pay 10% annual interest and mature in 12 months, or earlier upon completion of the company’s previously announced proposed U.S. public offering. The debenture will be secured under a general security agreement dated March 7, 2025, with related security interests filed in Alberta. Innocan said it expects the offering to close on or around March 12, 2026, and intends to use the proceeds for working capital and NYSE listing-related costs. Tamar Innovest holds 17% of Innocan’s common shares and is managed by Ralph Bossino, a director of the company.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innocan Pharma Ltd. published the original content used to generate this news brief via CNW (Ref. ID: 202603111842CANADANWCANADAPR_C7838) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1670710588.SGD","symbol_name":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL58mr6g:1","article_id":"2618971780","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618971780","pubTimestamp":1773268994,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innocan said it plans to issue a debenture to its largest shareholder, Tamar Innovest, for gross proceeds of USD 450,000. The debenture will pay 10% annual interest and mature in 12 months, or earlier upon completion of the company’s previously announced proposed U.S. public offering. The debenture will be secured under a general security agreement dated March 7, 2025, with related security interests filed in Alberta. Innocan said it expects the offering to close on or around March 12, 2026, and intends to use the proceeds for working capital and NYSE listing-related costs. Tamar Innovest holds 17% of Innocan’s common shares and is managed by Ralph Bossino, a director of the company.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","BK4585":"ETF&股票定投概念","AMCR":"AMCOR PLC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","BK4588":"碎股","BK4136":"纸材料包装","BK4597":"股息贵族"},"translate_title":"Innocan Pharma将向Tamar Innovest发行450,000美元10%债券","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMCR":0.9},"content_text":"Innocan Pharma to issue USD 450,000 10% debenture to Tamar Innovest\n    \n\n        Innocan said it plans to issue a debenture to its largest shareholder, Tamar Innovest, for gross proceeds of USD 450,000. The debenture will pay 10% annual interest and mature in 12 months, or earlier upon completion of the company’s previously announced proposed U.S. public offering. The debenture will be secured under a general security agreement dated March 7, 2025, with related security interests filed in Alberta. Innocan said it expects the offering to close on or around March 12, 2026, and intends to use the proceeds for working capital and NYSE listing-related costs. Tamar Innovest holds 17% of Innocan’s common shares and is managed by Ralph Bossino, a director of the company.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innocan Pharma Ltd. published the original content used to generate this news brief via CNW (Ref. ID: 202603111842CANADANWCANADAPR_C7838) on March 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618971780","isCrawlerRequest":true}